EIKN Eikon Therapeutics, Inc.
7.295USD-3.25%Mkt Cap: 408.40M $P/E: —Today
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR…
Industry Peers
Biotechnology$128.08BUSDP/E 29.4
$78.44BUSD
$76.40BUSDP/E 18.4
$58.08BUSDP/E 35.4
$48.23BUSDP/E 31.4
$43.05BUSD
$41.82BUSDP/E 17.8
$41.41BUSDP/E 65.1
$32.80BUSDP/E 30.2
$30.03BUSDP/E 37.8
$25.10BUSD
$23.93BUSD
$22.99BUSDP/E 14.5
$22.54BUSDP/E 28.9
$22.22BUSD
$21.10BUSDP/E 29.1
$15.03BUSDP/E 17.5
$15.01BUSDP/E 15.8
$14.48BUSDP/E 18.4
$14.32BUSD
| Headline | Source | Time |
|---|---|---|
Older | ||
 Eikon Therapeutics Eyes Safer PARP1 Cancer Treatments With EIK1003, EIK1004 Eikon Therapeutics (NASDAQ:EIKN) outlined its development strategy for selective PARP1 inhibitors and its Werner helicase inhibitor during a discussion hosted by Cantor biotech analyst Imogen Mansfield. President, Chief Executive Officer and Board Chair Roger Perlmutter and MD Anderson Cancer Center | ||